Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma

Publikation

Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma

Wissenschaftlicher Artikel/Review - 27.02.2007

Hau P, Koch H, Jauch T, Schuth J, Rieckmann P, Brenner A, Rauch M, Rudolph R, Bauer B, Marg E, Hundsberger Thomas, Koch D, Bogdahn U

Zitation

Hau P, Koch H, Jauch T, Schuth J, Rieckmann P, Brenner A, Rauch M, Rudolph R, Bauer B, Marg E, Hundsberger T, Koch D, Bogdahn U. Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology 2007; 68:688-90.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Neurology 2007; 68

Veröffentlichungsdatum

27.02.2007

eISSN (Online)

1526-632X

Seiten

688-90

Kurzbeschreibung/Zielsetzung

We surveyed neuro-oncologists regarding patients treated with temozolomide for at least 12 cycles or 12 months. Patients receiving first-line temozolomide for a median 13 cycles had a median progression-free survival (PFS) of 14 months. Patients with recurrent disease receiving a median 14 cycles had a median PFS of 15.5 months. A small percentage of patients experienced grade III to IV toxicity. These results suggest that long-term treatment with temozolomide is feasible and well tolerated.